Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
Rhea-AI Summary
Ocular Therapeutix (NASDAQ: OCUL) will report first-quarter 2026 financial results and host a live conference call and webcast on May 5, 2026 at 8:00 AM ET. The company will discuss business progress and results for the quarter ended March 31, 2026. A replay will be archived for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – OCUL
In the Apr 28 session, OCUL declined 2.10%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 27 | Conference participation | Positive | +0.3% | Planned May scientific and investor conference presentations including Phase 3 data. |
| Apr 22 | Investor event | Positive | +3.5% | Announcement of June 17, 2026 Investor Day with leadership and KOLs. |
| Apr 14 | Inducement grants | Negative | -1.1% | Equity inducement awards and options/RSUs granted to new employees and SVP. |
| Apr 13 | Clinical data update | Positive | +0.8% | Additional positive Week 52 SOL-1 Phase 3 AXPAXLI data in wet AMD. |
| Apr 01 | Conference presentations | Positive | -1.6% | Plans to present further SOL-1 Phase 3 data at April conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news — mainly clinical updates and event participation — has generally seen modest price alignment, with one conference update drawing a negative divergence.
Over the past month, OCUL has highlighted multiple investor and scientific events, inducement equity grants, and additional positive Week 52 SOL-1 Phase 3 data for AXPAXLI. Conference and Investor Day announcements on April 1, April 22, and April 27, 2026 produced small price moves, mostly positive. The current earnings-date announcement fits a pattern of frequent investor communications around key clinical progress and upcoming presentations.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, May 5, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the first quarter ended March 31, 2026.
Conference Call and Webcast Information:
Date: Tuesday, May 5, 2026 at 8:00 AM ET
Participant Dial-In (U.S.): 1-800-343-4136
Participant Dial-In (International): 1-203-518-9843
Conference ID: OCULAR (required for entry)
Webcast Access: Please click here
The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
